Реферат
The aim of this study was to estimate the seroprevalence of immunoglobulin M (IgM) and G (IgG) antibodies against SARS-CoV-2 in asymptomatic people in Wuhan. This was a cross-sectional study, which enrolled 18,712 asymptomatic participants from 154 work units in Wuhan. Pearson Chi-square test,
Тема - темы
Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Female , Humans , Male , Middle Aged , Young Adult , Antibodies, Viral/blood , COVID-19/immunology , Carrier State/immunology , China/epidemiology , Coronavirus Nucleocapsid Proteins/immunology , Cross-Sectional Studies , Immunoglobulin G/blood , Immunoglobulin M/blood , Occupations/classification , Phosphoproteins/immunology , SARS-CoV-2/immunology , Seroepidemiologic Studies , Spike Glycoprotein, Coronavirus/immunologyТема - темы
Humans , Animals , Female , Adult , Middle Aged , Young Adult , Pneumonia, Viral/prevention & control , Vaccines, Synthetic/immunology , Coronavirus Infections/prevention & control , Pneumonia, Viral/immunology , Vaccines, Synthetic/adverse effects , Randomized Controlled Trials as Topic , Immunization, Secondary , Clinical Trials, Phase III as Topic , Coronavirus Infections/immunology , Spike Glycoprotein, Coronavirus/genetics , Spike Glycoprotein, Coronavirus/immunology , Injections, Intramuscular , Moscow , Antibodies, Viral/bloodРеферат
The development of an effective vaccine against SARSCoV-2 has turned into a global priority in order to stop the advance of this ongoing COVID-19 pandemic. To date there are 25 candidate vaccines currently in a clinical trial stage, 3 of which have been subjected to phase I/II preliminary reports (ChAdOx1 nCoV-19, BNT162b1 and mRNA-1273). These vaccines have demonstrated to elicit robust cellular and humoral immune responses when compared to convalescent patients serum samples and have shown an acceptable safety profile with no reported severe side effects. Here we discuss the reported evidence regarding these vaccines.